Abstract
Naproxen and flurbiprofen form complexes with hydroxypropyl-β-cyclodextrin; with stability constants of 2207 and 12515 M −1 respectively. However, only small fractions of the drug remain complexed when the drug–cyclodextrin complex is added to plasma in vitro. This result can be explained by albumin effectively competing with cyclodextrin for drug binding and by the simultaneous displacement of the drug from cyclodextrins by plasma cholesterol. Naproxen and flurbiprofen were administered intravenously to rats as cyclodextrin complexes. The disposition in the body of naproxen was not significantly altered by the complexation. This indicates that immediately after administration all drug is removed from the cyclodextrin complex. However, the initial distribution of flurbiprofen was changed upon complexation. Drug concentrations in liver, brain, kidney, and spleen were increased, indicating that hydroxypropyl-β-cyclodextrin may improve the presentation of the flurbiprofen to biomembranes, as compared with plasma proteins. The effect was transient; 60 min after injection the differences in tissue concentration compared with controls were dissipated. Finally, the importance of protein binding in determining the mode of interaction of cyclodextrins on drug disposition is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
M. E. Brewster, K. S. Estes, T. Loftsson, R. Perchalski, H. Derendorf, G. Mullersman, and N. Bodor. Improved delivery through biological membranes. XXXI. Solubilization and stabilization of an estradiol chemical delivery system by modified β-cyclodextrins. J. Pharm. Sci. 77:981–985 (1988).
G. Taylor, J. Weiss, and J. Pitha. Testosteron in a cyclodextrin-containing formulation: Behavioral and physiological effects of episode-like pulses in rats. Pharm. Res. 6:641–646 (1989).
M. Kajtar, M. Vikmon, E. Morlin, and J. Szejtli. Aggregation of amphotericin B in the presence of γ-cyclodextrin. Biopolymers 28:1585–1596 (1989).
K. Uekama, F. Hirayama, T. Wakuda, and M. Otagiri. Effects of cyclodextrins on the hydrolysis of prostacyclin and its methyl ester in aqueous solution. Chem. Pharm. Bull. 29:213–219 (1981).
F. Hirayama, M. Kunhara, and K. Uekama. Mechanisms of deceleration by methylated cyclodextrins in the dehydration of prostaglandin E2 and the isomerization of prostaglandin A2 in aqueous solution. Chem Pharm. Bull. 34:5093–5101 (1986).
F. Hirayama, M. Kurihara, and K. Uekama. Improvement of chemical instability of prostacyclin in aqueous solution by complexation with methylated cyclodextrins. Int. J. Pharm. 35:193–199 (1987).
O. Bekers, J. H. Beijnen, E. H. Groot Brammel, M. Otagiri, A. Bult, and W. J. M. Underberg. Stabilization of mitomycins on complexation with cyclodextrins in aqueous acid media. Int. J. Pharm. 52:239–248 (1989).
M. Otagiri, K. Uekama, T. Irie, M. Sunada, T. Miyata, and Y. Kase. Effects of cyclodextrins on the hemolysis induced with phenothiazide neuroleptics. In J. Szejtli (ed.), I. Int. Symp. Cyclodextrins Budapest, 1981, D. Reidel, Dortrecht, 1982, pp. 389–398.
K. Uekama, T. Irie, M. Sunada, M. Otagiri, K. Iwasaki, Y. Okano, T. Miyata, and K. Kase. Effects of cyclodextrins on chlorpromazine-induced haemolysis and central nervous system responses. J. Pharm. Pharmacol. 33:707–710 (1981).
T. Hoshino, F. Hirayama, K. Uekama, and M. Yamasaki. Reduction of protriptyline-photosensitized hemolysis by β-cyclodextrin complexations. Int. J. Pharm. 50:45–52 (1989).
T. Irie, M. Otagiri, K. Uekama, Y. Okano, and T. Miyata. Alleviation of the chlorpromazine-induced muscular tissue damage by β-cyclodextrin complexation. J. Incl. Phenom. 2:637–644 (1984).
T. Irie, S. Kuwahar, M. Otagiri, K. Uekama, and T. Iwamasa. Reduction in the local tissue toxicity of chlorpromazine by β-cyclodextrin complexation. J. Pharmacobio-Dyn. 6:790–792 (1983).
T. Nagai, O. Shirakura, and N. Nambu. Hypnotic potency, and the plasma and the brain concentration of hexobarbital in the presence of cyclodextrins. In 3rd Int. Conf. Pharm. Technol., Paris, 31 May/2 June 1983, Vol. V, pp. 253–262.
O. Shirakura, N. Nambu, and T. Nagai. Effect of β-cyclodextrin on disposition of hexobarbital and phenobarbital in mice. J. Inch Phenom. 2:613–621 (1984).
K. Arimori and K. Uekama. Effects of β-and γ-cyclodextrins on the pharmacokinetic behaviour of prednisolone after intravenous and intramuscular administration to rabbits J. Pharmacobio-Dyn. 10:390–395 (1987).
H. W. Frijlink, J. Visser, N. R. Hefting, R. Oosting, D. K. F. Meijer, and C. F. Lerk. The pharmacokinetics of β-cyclodextrin in the rat. Pharm. Res. 7:1248–1252 (1990).
H. W. Frijlink, A. C. Eissens, N. R Hefting, K. Poelstra, C. F. Lerk, and D. K. F. Meijer. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat. Pharm. Res. 8:9–16 (1991).
T. Higuchi and K. Connors. Phase-solubility techniques. Adv. Anal. Chem. Instr. 4:117–212 (1965).
H. W. Frijlink, J. Visser, and B. F. H. Drenth. Determination of cyclodextrins in biological fluids by high-performance liquid chromatography with negative colorimetric detection using post-column complexation with phenolphthalein. J. Chromatogr. 415:325–333 (1987).
J. H. Lin, D. M. Cocchetto, and D. E. Duggan. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin. Pharmacokinet. 12:402–432 (1987).
F. Cramer and H. Hettler. Inclusion compounds of cyclodextrins. Naturwissenschaften 54:624–632 (1967).
J. J. Vallner. Binding of drugs by albumin and plasma protein. J. Pharm. Sci. 66:447–465 (1977).
M. H. Bickel, R. M. Raaflaub, M. Hellmuller, and E. J. Stauffer. Characterization of drug distribution and binding competition by two-chamber and multi-chamber distribution dialysis. J. Pharm. Sci. 76:68–74 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Frijlink, H.W., Franssen, E.J.F., Eissens, A.C. et al. The Effects of Cyclodextrins on the Disposition of Intravenously Injected Drugs in the Rat. Pharm Res 8, 380–384 (1991). https://doi.org/10.1023/A:1015857902238
Issue Date:
DOI: https://doi.org/10.1023/A:1015857902238